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The biological role of secrotogranin II is unknown but it has been suggested that the protein may function as a precursor of one or more biologically 
active neuroendocrine peptides. We have isolated a 33 amino acid-residue peptide from the brain of the frog Rurra ridibundn that shows strong 
(82%) homology with human presecretogranin II-(I82-204)-peptide. This region of secretogranin II has also been very strongly conserved in the 
rat and bovine proteins, Analysis of the nucleotide sequence of the mammalian secretogranin II cDNAs indicates that the peptide sequence is 
Ranked by two Lys-Arg dibasic residue processing sites, It is proposed, therefore, that this fragment represents a specific product of the post-transla- 
tional processing of secretogranin II and, by analogy with peptides derived from chromogranin A, may be important in the regulation of neurosecre- 
tion. 
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1. INTRODUCTION 
Secretogranin II (previously termed chromogranin C) 
is an acidic protein containing sulphated tyrosine 
residues that was identified independently in the 
anterior pituitary [I] and in chromaffin granules of the 
adrenal medulla [2] and subsequently shown to be pres- 
ent in most tissues of the neuroendocrine system (re- 
viewed in [3]). The complete primary structure of 
s~cretogranin II may be deduced from the nucleotide se- 
quence of cIoned DNA complementary to human [4], 
rat [5] and bovine [3] secretogranin II mRNAs. In 
secretory vesicles, secretogranin II is proteolytically 
cleaved in a tissue specific manner to a range of frag- 
ments of intermediate size [6]. In chromaffin granules, 
for example, 50% of the protein is processed to as yet 
uncharacterized peptides. The biological function of 
secretogranin II is unknown and it has been specuIated 
that its action may be mediated through such peptide 
fragments [3,4]. Neuroendocrine peptides are generally 
generated from precursor proteins by proteolytic 
cleavage at the site of pairs (or groups) of basic amino 
acids [7]. The sequence of secr~togranin II contains 
nine such dibasic pairs (Lys-Arg and Arg-Lys), con- 
served across species, that represent potential recogni- 
tion sites for a processing enzyme. In a recent study, we 
have purified an wMSH release-inhibiting factor 
Currespottc/ct~cc w/dress: J .M. ConIon, Dcp;lrtmctH or Biomedical 
Scicnccs, Creil;hlon University School of Mcdicinc, Omahs NE 
68 17% USA. Fax: (I) (402) 280 26’30. 
(melanostatin) from an extract of frog brain [8]. A 
systematic search of side-fractions from this purifica- 
tion for other potential neuroendocrine peptides has led 
to the identification of a fragment of secretogranin II 
that has arisen by proteolytic cleavage at dibasic residue 
processing sites. 
2. MATERIALS AND METHODS 
2. I. Tissue exfructioa 
The extraction of whole brain (94.5 g) from 12GOspecimens of adult 
Ratra ridiibuttda has been described previously 181. Peptides were 
isolated from the extract using Sep-Pak Cl8 cartridges (Waters 
Associates). Bound material was recovered by elution with 70070 (v/v) 
aeetonitrile/~vater ;tnd freeze-dried. 
2.2. Purification of rhe peptide 
The brain extract was redissolved in 1% (v/v) trifluoroacetic acid 
(10 ml) and chromatographed on a (100x2.5 cm) column of 
Sephacryl S-100 (Pharmacia) equilibrated with I M acetic acid at a 
flow rate of 120 mI/h. Fractions (10 ml) were collected and absor- 
bance was monitored at 280 nm. Fractions with K,, between 0.24 and 
0.39, containing mclanoslatin activity, were pooled and 50% of the 
total volume was pumped at a flow rate of 2 ml/min onto a (250x IO 
mm) Vydac 218TP54 Ci8 column (Separations Group) equilibrated 
with O,l% (vt’v) trifluoroaceIic acid/water, The concentration of 
acetonitrilc in the cluting solvent was raised to 21% (v/v) over iOmin. 
held at rhis conccntralion for 30 min, and raised to 49% over 60 min 
using a linear gradient. Absorbance was monitored at 214 nm and 280 
run, and peaks were collected manually without using a fraction col- 
lector. The peak denoted by the arrow (Fig. 1) was re-chrol~la~o- 
graphed on a (250x 10 mm) Ultrapore RPSC C3 column (Beckman) 
cquilitwted wirh acrlnnitrile/wnter/triflll~roncrtic acid (21.0:78.9 
: 0. I) at a flow rate of 1.5 ml/min. The concentration of acclonitrilc 
in the cluting solvent was raised to 42% (v/v) over 45 min using a 
linear ~t~dienl. 
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2.3. Chomcterization of the peptide 
The amino acid composition of the peptide was determined by pre- 
column derivatization with phenylisothiocyanate and its primary 
structure was determined by automated Edman degradation using 
procedures previously described [8J. 
3. RESULTS 
3,1. Pwifcation of the secretogranin fragment 
The elution profiIe on a semi-preparative Vydac Cl8 
column of the extract of frog brain, after partial 
purification by gel permeation chromatography, is 
shown in Fig. 1, The prominent peak denoted by M 
contained melanostatin [8]. All the major peaks in the 
chromatogram were re-chromatographed on a semi- 
preparative Ultrapore C3 column. The elution profile 
of the fraction containing the peak denoted by the ar- 
row is shown in Fig. 2. The peak denoted by the bar 
contained the secretogranin II fragment. The peptide 
was eluted from an analytical Vydac C4 column as a 
sharp and symmetrical peak (~hromatogr~m not 
shown) and the yield of pure peptide was approximately 
4 nmol. 
3.2. Structurd characterization 
Amino acid analysis of the secretogranin fragment 
indicated a total af 33 amino acids excluding possible 
tryptophan and cysteine residues. The following com- 
position was obtained: Asx 3,0, Glx 8.4, Ser 2.0, Gly 
3.2, Thr 3.0, Ala 2.1, Pro 1.1, Tyr 0.9, Val 1.6, Ile 0.8, 
Leu 3.8, Phe 1.0, Lys 2.0 (residues/m01 peptide). The 
primary structure of the peptide was determined by 
automated Edman degradation. Unambiguous assign- 
ment of phenylthiohydantoin amino acid derivatives 
was possible for 33 cycles of operation of the se- 
quenator and the proposed amino acid sequence of the 
peptide is shown in Table I. Agreement between the se- 
quence analysis and the amino acid composition data 
was good, demonstrating that the Full sequence of the 
peptide had been obtained. The peptide was identified 
as a fragment of secretogranin II (corresponding to 
d&---?h _-_ y,-_-~- -. j=---~_-lo 
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Fig. 2. Purification to near homogeneity of a fragment of frog 
secretogranin II on a semi-preparative Ultrapore C-3 column:. The 
peak containing the fragment is shown by the bar. 
residues (182-204) of human prese~retogranin II) using 
the FASTA Protein Sequence Data Base [9]. 
4. DISCUSSION 
This study has shown that secretogranin II is present 
in neuroendocrine tissue of amphibia as well as mam- 
mals and that the protein is proteolytica~ly processed to 
a smaller fragment. Table I shows a comparison of the 
amino acid sequence of the frog secretogranin II frag- 
ment with the sequences of corresponding regions of 
human, rat and bovine secretogranins (predicted from 
the nucteotide sequences of cDNAs) [3-51. Evolu- 
tionary pressure to conserve this region of the protein 
has been very strong, consistent with a possible 
regulatory role for the peptide. In the mammalian 
secretogranins, the peptide fragment sequence is flank- 
ed by pairs of basic amino acids and conformational 
analysis indicates that these processing sites, as is the 
case with many prohormones, are located adjacent to 
regions of the protein with a high probability of &turn 
formation [IO]. 
Chromogranin A, like secretogranin II, contains 9 
dibasic residue potentia1 processing sites and post- 
translational processing can generate biologically active 
peptides. Pancreastatin, a peptide i’irst isolated from 
porcine pancreas that inhibits insulin release in rats [I 1 J 
was subsequently shown to represent a fragment of 
chromogranin A [ 121. More recently a second fragment 
of chromogranin A, chromostatin, was found to inhibit 
catecllolamine secretion from adrenal chroInaffin cefls 
[131* The post-translational processing of 
chromogranil~ B has been studied less extensively but a 
fragment of uni:no*Nn function, comprising 
chrornogranin BW(420-493).peptide, hasbeen shown to 
have a widespread istribution in the central nervous 
system of mammals [14]. l-‘urthcr studies are clearly 
warranted to determit~e ~~ll~ther the se~reto~ranin II 
fraymcnt isolated in this study has effects on ueurocn- 
docrinc sccrction, 
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Table I 
A comparison of the amino acid sequence of a fragment of frog secretogranin II with the predicted 
sequences of the corresponding region of human, bovine and rat secretogranin II 
Jttrlo 1991 
Frog TNEIV EEQYT PQSLA TLQSV FQELG KLKGQ ANN 
Human EKR3 ---_- -Em__ -_--- -- E _- ----- --T-P N-QCKRI 
Rat CKR3 _____ -E___ -__-- m-E_- B-m-_ --T-P S-QCKRI 
Bcvi ne IKRI --_-- -E--m --N-w --E-m ----,_ --T-P NSQCKRI 
f-) denotes residue identity. Theboxed residuesareputative sites 
of post-t~enslationaL processingof secretogranin 11. 
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